Hiroshi Ishii

机构：Kanazawa University, National Institute of Infectious Diseases, Chiba Cancer Center · ORCID：0000-0002-3295-4867

发表论文 300 篇 · 总被引 7558 次 · h-index 49

代表论文

• Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial (2023 · The Lancet · 被引 253)
• A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407) (2022 · European Journal of Cancer · 被引 91)
• Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer (2020 · Nature Communications · 被引 62)
• nal‐IRI+5‐FU/LV versus 5‐FU/LV in post‐gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients (2020 · Cancer Medicine · 被引 50)
• Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials (2020 · Japanese Journal of Clinical Oncology · 被引 40)
• Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group trial, JCOG1106 (2020 · Japanese Journal of Clinical Oncology · 被引 35)